| HOME >> BIOLOGY >> TECHNOLOGY |
LEXINGTON, Mass., Jan. 5 /PRNewswire/ -- RainDance Technologies, Inc., a provider of innovative microdroplet-based solutions for human health and disease research, today announced that it has been selected to share in the first-ever round of cooperative research grants by The Massachusetts Life Sciences Center (MLSC).
The MLSC awarded a grant of $250,000 per year for three years to Dr. David
Weitz, Mallinckrodt Professor of Physics and Applied Physics at
"The grant award is particularly dramatic for us as it represents entry into new and exciting applications of our ground-breaking RainStorm(TM) microdroplet-based technology," said Chris McNary, President and Chief Executive Officer of RainDance Technologies.
"To date, we have focused application of our RainStorm(TM) micro-droplet technology, which produces picoliter-volume droplets at a rate of 10 million per hour, in two key areas: One, the targeted resequencing of the human genome -- stirring significant interest and excitement in one of the fastest-growing segments of the $1 billion DNA sequencing market -- and two, the development of the next generation of high-throughput screening (HTS) and small molecule storage for the drug discovery market," McNary said.
"In effect, the MLSC grant -- awarded after rigorous review by the Life
Sciences Center's Scientific Advisory Board -- recognizes the even broader
capabilities of droplet biology for its potential to accelerate health and
human dis
'/>"/>
| SOURCE RainDance Technologies, Inc. Copyright©2009 PR Newswire. All rights reserved |